Evidence map›Paper›PMID 33330804›Full record

ArticleGlobal health & medicine2020

Metabolic changes of Japanese schizophrenic patients transferred from hospitalization to outpatients.

Yoriyasu Uju, Tetsuto Kanzaki, Yuki Yamasaki, Tadayuki Kondo, Hideki Nanasawa, Yu Takeuchi, Yuta Yanagisawa, Shun Kusanishi, Chieko Nakano, Tetsuro Enomoto and 6 more

Abstract read
In one paragraph

Article in Global health & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yoriyasu UjuDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Tetsuto KanzakiDepartment of Drug Informatics, Graduate School and Faculty of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Yuki YamasakiDepartment of Drug Informatics, Graduate School and Faculty of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Tadayuki KondoDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Hideki NanasawaDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Yu TakeuchiDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Yuta YanagisawaDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Shun KusanishiDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Chieko NakanoDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Tetsuro EnomotoDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Akahito SakoDepartment of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Hidekatsu YanaiDepartment of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Seisuke MimoriDepartment of Clinical Medicine, Faculty of Pharmacy, Chiba Institute of Science, Chiba, Japan.
Kazuei IgarashiAmine Pharma Research Institute, Innovation Plaza at Chiba University, Chiba, Japan.
Tsuyoshi TakizawaDepartment of Biostatistics, Faculty of Pharmacy, Chiba Institute of Science, Chiba, Japan.
Tatsuro HayakawaDepartment of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well known that schizophrenic patients have high incidence of metabolic syndrome and life-style related diseases. There are reports that the rates of these diseases are increased more in outpatients than inpatients, but are also reports that the rates are not different between both patient groups. These differences might be related to the length of hospitalization. Hospitalization of Japanese psychiatric patients is about 300 days, much longer than western countries (below 50 days). Therefore, we investigated lipid and glucose metabolism of schizophrenic patients transferred from hospitalization to outpatients at Kohnodai hospital with a mean of 80 days hospitalization period to clarify metabolic characteristics in Japanese patients. Study participants were 144 schizophrenia inpatients and 109 outpatients at Kohnodai Hospital. These 109 outpatients were followed for approximately 2 years, without changes of administrated drugs, and from 144 inpatients. Data from outpatients were obtained at 6 months, 1 year and 2 years after their discharge. Outpatients 2 years after discharge had significantly higher levels of total cholesterol, triglyceride and non-high density lipoprotein (non-HDL) cholesterol than inpatients, accompanied with an increase of body weight. Serum HDL-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) levels had no significant difference between both groups. These lipids and glucose levels also showed the same tendency in outpatients 0.5 year and 1 year after discharge as those after 2 years. We found that schizophrenic patients in our study appeared to have changes of lipid metabolism 2 years after their discharge, but no significant changes of glucose metabolism, such as FPG and HbA1c.

Indexed as

glucose metabolisminpatientslipid metabolismoutpatientsschizophrenia

Identifiers

PMID33330804
PMCPMC7731271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.